These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34831094)

  • 1. Chemotherapy-Induced Hepatotoxicity in HIV Patients.
    Bressan S; Pierantoni A; Sharifi S; Facchini S; Quagliarello V; Berretta M; Montopoli M
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
    Sulkowski MS; Thomas DL; Chaisson RE; Moore RD
    JAMA; 2000 Jan; 283(1):74-80. PubMed ID: 10632283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
    Mancuso A; Zavaglia C; Bai F; Puoti M; Belli LS
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1414-6. PubMed ID: 24206381
    [No Abstract]   [Full Text] [Related]  

  • 4. Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV/HBV coinfection.
    Nampala H; Luboobi LS; Mugisha JYT; Obua C; Jablonska-Sabuka M
    Math Biosci; 2018 Aug; 302():67-79. PubMed ID: 29800563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy.
    Olin JL; Klibanov O; Chan A; Spooner LM
    Ann Pharmacother; 2019 Aug; 53(8):812-832. PubMed ID: 30770025
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
    Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
    J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.
    Orenstein R; Tsogas N
    Pharmacotherapy; 2002 Nov; 22(11):1468-78. PubMed ID: 12432973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver disease in the HIV-infected individual.
    Price JC; Thio CL
    Clin Gastroenterol Hepatol; 2010 Dec; 8(12):1002-12. PubMed ID: 20851211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug use and antiretroviral therapy (ART) interactions: a qualitative study to explore the knowledge, beliefs, adherence, and quality of life of people living with HIV taking ART and illicit drugs.
    Fuster-RuizdeApodaca MJ; Castro-Granell V; Laguía A; Jaén Á; Cenoz S; Galindo MJ
    AIDS Res Ther; 2020 May; 17(1):24. PubMed ID: 32448214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.
    Bhattacharya D; Gupta A; Tierney C; Huang S; Peters MG; Chipato T; Martinson F; Mohtashemi N; Dula D; George K; Chaktoura N; Klingman KL; Gnanashanmugam D; Currier JS; Fowler MG
    Clin Infect Dis; 2021 Apr; 72(8):1342-1349. PubMed ID: 32161944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.
    Frega S; Ferro A; Bonanno L; Guarneri V; Conte P; Pasello G
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111093
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits.
    Powderly WG
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S109-13. PubMed ID: 14986283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.
    Uberti-Foppa C; De Bona A; Morsica G; Galli L; Gallotta G; Boeri E; Lazzarin A
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):146-52. PubMed ID: 12794546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
    PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
    J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.
    Priyanka PSSL; Varma DM; Immadisetti K; Rajesh R; Vidyasagar S; Guddattu V
    Int J Risk Saf Med; 2017; 29(1-2):25-55. PubMed ID: 28885219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
    Rudek MA; Flexner C; Ambinder RF
    Lancet Oncol; 2011 Sep; 12(9):905-12. PubMed ID: 21570912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
    J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.